IFNAR2
IFNAR2 (Interferon alpha/beta receptor 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.
Overview
Together with IFNAR1, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signalling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another.
Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.61, genetic association 0.00, clinical 0.98).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · IFNAR2 (Interferon alpha/beta receptor 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.
- 1 · What it is
IFNAR2 (Interferon alpha/beta receptor 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.
- 2 · What goes wrong in cancer
Together with IFNAR1, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa).
- 3 · How drugs use it
No product in this corpus aims at IFNAR2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:5433 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P48551 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000159110 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: melanoma 0.59, acute lymphoblastic leukaemia 0.53, B-cell chronic lymphocytic leukaemia 0.51, plasma cell myeloma 0.50, non-Hodgkin lymphoma 0.57, chronic myelogenous leukaemia, BCR-ABL1 positive 0.53 (GraphQL API, CC0))
Biology
Together with IFNAR1, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signalling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another. The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors (STAT1, STAT2 and STAT). STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes. Potent inhibitor of type I IFN receptor activity. Location: Cell membrane; Secreted (UniProt). Locus 21q22.11 (HGNC).
- Myeloproliferative neoplasms: Open Targets association 0.60 with myeloproliferative neoplasm (MONDO_0020076)
- Leukaemia: Open Targets association 0.58 with leukaemia (MONDO_0005059)
- Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908)
- Multiple myeloma: Open Targets association 0.50 with plasma cell myeloma (MONDO_0009693)
- Melanoma: Open Targets association 0.59 with melanoma (MONDO_0005105)
- Polycythaemia vera: Open Targets association 0.58 with acquired polycythemia vera (MONDO_0009891)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.98. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"IFNAR2" OR ABSTRACT:"IFNAR2" OR TITLE:"interferon alpha and beta receptor subunit 2" OR ABSTRACT:"interferon alpha and beta receptor subunit 2" OR TITLE:"Interferon alpha/beta receptor 2" OR ABSTRACT:"Interferon alpha/beta receptor 2" OR TITLE:"IFNABR" OR ABSTRACT:"IFNABR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IFNAR2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetFGR
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types).
- TargetFYN
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types).
- TargetSRMS
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types).
- TargetBLK
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types).
- TargetIMPDH1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetYES1
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types).
- TargetRPL10
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Multiple myeloma.
- TargetAFF1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Melanoma.